Abstract: The invention relates to murine monoclonal antibodies (MAbs), A, B, C and D, which are directed against tumor-associated antigens. The nearly complete nucleotide sequences of the V genes of these MAbs are described, so that the relevant variable domains can be put together to give chimeric MAbs, or “humanized” MAbs are obtained by inserting the hypervariable regions (complementarity determining regions=CDR) into a human MAb framework. Antibody constructs of this type can be employed in human therapy and in vivo diagnosis without the disadvantages observed with murine MAbs.

Abstract: Glycosylated prodrugs, a preparation method therefor, and their use with tumor-specific immunoenzymatic conjugates for the treatment of cancer, are described. These anthracycline prodrugs have formula (I).

Abstract: Compounds of the formula I ##STR1## in which the substituents R.sub.1 -R.sub.5 and n and m are as defined are suitable for controlling tumors.

Abstract: The use of products of formula (I) is described, wherein X and Y represent hydrogen, hydroxy or alkoxy; and R.sub.1 and R.sub.2 represent H, alkyl, alkenyl or alkynyl, arylalkyl, acyl or R.sub.1 and R.sub.2 together with nitrogen form a heterocycle for preparing an antitumoral drug.

Abstract: R.sup.2 is H or OH;R.sup.3 is H, OH, OCH.sub.3, CH.sub.3 or NH.sub.2 ;Rhu 4 is H, OH, OCH.sub.3, NH.sub.2 or ##STR2## The compounds of the formula I are prepared by fermentation of the strain Streptomyces parvulus DSM 40722 in the presence of substituted benzoic acids of the general formula II ##STR3## where R.sup.1 is H or OH;R.sup.2 is H or OH;R.sup.3 is H, OH, OCH.sub.3, CH.sub.3 or NH.sub.2 ;R.sup.4 is H, OH, OCH.sub.3 or NH.sub.2,and they inhibit Leukocyte elastase and can be used as pharmaceuticals.

Abstract: Pharmaceuticals containing or composed of at least one compound of the formula I and/or one of its physiologically tolerated salts where appropriate, where the compounds of the formula I can, where appropriate, be in the form of pure stereoisomers or mixtures thereof; formula I is: ##STR1## in which R.sup.1 =organic radical or halogen,A=C,C single or C,C double bond,n=0, 1 or 2, and ##STR2## R.sup.2 and R.sup.3 =H or optionally substituted aliphatic radical. The pharmaceuticals are suitable for the prophylaxis and/or treatment of diseases of the immune system, especially of tumors, infections and/or autoimmune diseases of the human or animal body and for use as adjuvants for vaccines.Some of the compounds of the formula I are new; the compounds can be prepared by special processes.

Abstract: The use of the thiazole derivative tiprotimod for the preparation of a pharmaceutical for the therapy of virus infections is described.

Abstract: The use of 15-deoxyspergualine for the preparation of a pharmaceutical for the therapy of degenerative diseases is claimed.

Abstract: A pharmaceutical formulation for the parenteral, in particular intravenous, administration of sparingly soluble substances is obtained when the very finely ground substance, with a maximum particle diameter of 3 .mu.m, is dispersed in an oil phase which contains emulsifier, and this mixture is emulsified with water for injection, is rendered isotonic and is homogenized using a high-pressure homogenizer, so that the resultant product is a solid/liquid/liquid disperse system.

Abstract: A fission product of an immunoglobulin having an immunologically functioning Fc-portion is bound to a carrier by adhesion or a chemical reaction. It can be used in an immunological analytic process for the determination of Fc-reactants in aqueous solutions.